These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 15800937

  • 1. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.
    Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G.
    Mov Disord; 2005 Aug; 20(8):958-63. PubMed ID: 15800937
    [Abstract] [Full Text] [Related]

  • 2. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study.
    Fernandez HH, Okun MS, Rodriguez RL, Malaty IA, Romrell J, Sun A, Wu SS, Pillarisetty S, Nyathappa A, Eisenschenk S.
    Int J Neurosci; 2009 Aug; 119(12):2196-205. PubMed ID: 19916848
    [Abstract] [Full Text] [Related]

  • 3. Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study.
    Paleacu D, Barak Y, Mirecky I, Mazeh D.
    Int J Geriatr Psychiatry; 2008 Apr; 23(4):393-400. PubMed ID: 17879256
    [Abstract] [Full Text] [Related]

  • 4. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration.
    Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C.
    Mov Disord; 2007 Feb 15; 22(3):313-8. PubMed ID: 17034006
    [Abstract] [Full Text] [Related]

  • 5. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.
    Int J Clin Pract; 2009 Apr 15; 63(4):613-23. PubMed ID: 19222614
    [Abstract] [Full Text] [Related]

  • 6. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG, Damier P, Hicking C, Laska E, Müller T, Olanow CW, Rascol O, Russ H.
    Mov Disord; 2007 Jan 15; 22(2):179-86. PubMed ID: 17094088
    [Abstract] [Full Text] [Related]

  • 7. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease.
    Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, Müller T, Kupsch A, Henningsen H, Oertel WH, Fuchs G, Kuhn W, Niklowitz P, Koch R, Herting B, Reichmann H, German Coenzyme Q(10) Study Group.
    Arch Neurol; 2007 Jul 15; 64(7):938-44. PubMed ID: 17502459
    [Abstract] [Full Text] [Related]

  • 8. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study.
    Vieta E, Calabrese JR, Goikolea JM, Raines S, Macfadden W, BOLDER Study Group.
    Bipolar Disord; 2007 Jun 15; 9(4):413-25. PubMed ID: 17547587
    [Abstract] [Full Text] [Related]

  • 9. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia.
    Reddy S, Factor SA, Molho ES, Feustel PJ.
    Mov Disord; 2002 Jul 15; 17(4):676-81. PubMed ID: 12210856
    [Abstract] [Full Text] [Related]

  • 10. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, randomised, placebo-controlled studies.
    Vieta E, Mullen J, Brecher M, Paulsson B, Jones M.
    Curr Med Res Opin; 2005 Jun 15; 21(6):923-34. PubMed ID: 15969892
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).
    Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, Calabrese JR, BOLDER II Study Group.
    J Clin Psychopharmacol; 2006 Dec 15; 26(6):600-9. PubMed ID: 17110817
    [Abstract] [Full Text] [Related]

  • 12. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group.
    Arch Neurol; 2005 Feb 15; 62(2):241-8. PubMed ID: 15710852
    [Abstract] [Full Text] [Related]

  • 13. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
    Okun MS, Fernandez HH, Rodriguez RL, Romrell J, Suelter M, Munson S, Louis ED, Mulligan T, Foster PS, Shenal BV, Armaghani SJ, Jacobson C, Wu S, Crucian G.
    Arch Neurol; 2006 May 15; 63(5):729-35. PubMed ID: 16682542
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read SC, Pratt R.
    Clin Ther; 2006 Feb 15; 28(2):266-79. PubMed ID: 16678648
    [Abstract] [Full Text] [Related]

  • 15. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease.
    Juncos JL, Roberts VJ, Evatt ML, Jewart RD, Wood CD, Potter LS, Jou HC, Yeung PP.
    Mov Disord; 2004 Jan 15; 19(1):29-35. PubMed ID: 14743357
    [Abstract] [Full Text] [Related]

  • 16. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study.
    Murata M, Hasegawa K, Kanazawa I, Japan Zonisamide on PD Study Group.
    Neurology; 2007 Jan 02; 68(1):45-50. PubMed ID: 17200492
    [Abstract] [Full Text] [Related]

  • 17. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A, Parkinson Study Group.
    Arch Neurol; 2004 Jul 02; 61(7):1044-53. PubMed ID: 15262734
    [Abstract] [Full Text] [Related]

  • 18. Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: Improvements in quality of life and quality of sleep.
    Endicott J, Paulsson B, Gustafsson U, Schiöler H, Hassan M.
    J Affect Disord; 2008 Dec 02; 111(2-3):306-19. PubMed ID: 18774180
    [Abstract] [Full Text] [Related]

  • 19. Rates of remission/euthymia with quetiapine monotherapy compared with placebo in patients with acute mania.
    Ketter TA, Jones M, Paulsson B.
    J Affect Disord; 2007 Dec 02; 100 Suppl 1():S45-53. PubMed ID: 17383011
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
    Ziegler M, Castro-Caldas A, Del Signore S, Rascol O.
    Mov Disord; 2003 Apr 02; 18(4):418-25. PubMed ID: 12671949
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.